Healthcare Industry News: electrotherapy
News Release - August 1, 2006
Zynex Medical Doubles Sales ForceExpansion of Direct Sales Force Positions Company for Continued Growth
LITTLETON, Colo.--(HSMN NewsFeed)--Aug. 1, 2006--Zynex Medical Holdings, Inc. (OTCBB: ZYNX ) has hired ten additional sales representatives resulting in a doubling of its US sales force over the past two months. The recent hiring was to satisfy an expanding interest in the Company's fully developed, FDA-cleared electrotherapy medical products.
The ten sales representatives joining the Zynex team are seasoned electrotherapy and medical-technology sales veterans. They represent decades of experience, and bring to Zynex a significant client base.
"This is a major milestone for Zynex, as we continue to execute our strategy, expand our reach and grow revenues in an already successful portion of our business," said Thomas Sandgaard, President and Chief Executive Officer. "Now, with the doubling of our sales force, we will be primed to gain a recognizable foothold in the much-larger direct sales market. It is our hope that, no matter where patients live, they will have immediate access to our safe, proven method of pain relief. Our mission is to improve quality of life, and we will now be able to offer our high-end electrotherapy products on a larger scale to truly make a marked difference."
About Zynex Medical Holdings, Inc.
Zynex Medical Holdings, Inc. (founded in 1996) engineers, manufactures, markets and sells its own design of electrotherapy medical devices in two distinct markets: standard digital electrotherapy products for pain relief and pain management; and the NeuroMove(TM) for stroke and spinal cord injury (SCI) rehabilitation. Zynex's product lines are fully developed, FDA-cleared and actively sold, and have been developed to uphold the Company's mission of improving the quality of life for patients suffering from impaired mobility due to stroke, spinal cord injury, or debilitating and chronic pain.
Safe Harbor Statement
Certain statements in this release are "forward-looking" and as such are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, risks and delays associated with product development, risk of market acceptance of products, technology or product obsolescence, competitive risks, reliance on manufacturing partners, dependence on reimbursement from insurance companies, additional capital needs and other risks described in our Form 10-KSB for the year ended December 31, 2005.
Source: Zynex Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.